A Phase 3 interventional study of insulin degludec and insulin aspart in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 124 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-06.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 33rd largest by enrollment, is one of 8 that started in 2011, is one of 49 in phase 3, and was the 23rd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Gan and Lee Pharmaceuticals, USA · Sites in Germany
Ages 18–70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–70
Yanbing Li
Ages 18–70
Tonghua Dongbao Pharmaceutical Co.,Ltd
Ages 18–75
By country, each count listing its studies:
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 50 · Phase 4 8
First in 2006; this study’s year is marked. 8 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 413 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 384 across the 70 interventional studies. Of the 64 that completed or were terminated, 51 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 70 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 127th largest by enrollment of the 428 interventional ones that give a count, is one of 23 that started in 2011, is one of 187 in phase 3, and was the 219th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing insulin degludec in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Europe and North America. The aim of this trial is to compare the efficacy and safety of adding liraglutide versus addition of insulin aspart with the largest meal to insulin degludec in subjects with type 2 diabetes.
Eligible subjects with an HbA1c equal to or above 7% at end of treatment in NN1250-3643 (NCT01193309) trial will be randomised to receive treatment intensification while subjects with an HbA1c below 7% at end of treatment in NN1250-3643 (NCT01193309) may continue to receive insulin degludec treatment. Subjects are to continue their pre-trial metformin treatment.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 413 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: insulin degludec
Drug: insulin degludec · Drug: insulin aspart
Drug: insulin degludec · Drug: liraglutide
Injected s.c. (under the skin) once daily. The doses will be individually adjusted
Injected s.c. (under the skin) once daily. The doses will be individually adjusted.
Injected s.c. (under the skin) once daily. The doses will be individually adjusted.
Change From Baseline in HbA1c (%) (Glycosylated Haemoglobin)
Values for change in HbA1c from baseline to 26 weeks of treatment period.
Time frame: week 0, week 26
Change From Baseline in Fasting Plasma Glucose (FPG)
Values for change in FPG in mmol/L from baseline to week 26 of randomised period.
Time frame: week 0, week 26
Change From Baseline in Body Weight
Corresponds to the values of change in body weight in kilograms from baseline to week 26.
Time frame: week 0, week 26
Number of Severe and Minor Treatment Emergent Hypoglycaemic Episodes
Corresponds to number of treatment emergent hypoglycaemic events from onset on or after the first day of exposure to investigational product and no later than 7 days after last exposure to investigational product. Confirmed hypoglycaemia was defined as the pool of severe hypoglycaemic episodes and minor episodes with a plasma glucose (PG) value \< 3.1 mmol/L (56 mg/dL).
Time frame: Onset on or after the first day of exposure to investigational product for 26 weeks of treatment period and no later than 7 days after last exposure to investigational product.
The trial was conducted at 119 sites in 12 countries: Austria (4), Belgium (4), Canada (15), Czech Republic (4), Denmark (6), Finland (6), France (4), Germany (12), Norway (6), Serbia (5), Spain (7) and United States (46). These sites enrolled subjects in the randomised or non-randomised arms of the trial.
| Milestone | IDeg | IDeg + Liraglutide | IDeg + IAsp OD |
|---|---|---|---|
| Started | 236 | 88 | 89 |
| Exposed | 234 | 87 | 86 |
| Completed | 224 | 76 | 75 |
| Not completed | 12 | 12 | 14 |
| Withdrew: Adverse event | 0 | 5 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 2 |
| Withdrew: Withdrawal criteria | 12 | 7 | 10 |
| Withdrew: Unclassified | 0 | 0 | 1 |
Values for change in HbA1c from baseline to 26 weeks of treatment period.
| percentage of glycosylated haemoglobin | IDeg | IDeg + Liraglutide | IDeg + IAsp OD |
|---|---|---|---|
| Change From Baseline in HbA1c (%) (Glycosylated Haemoglobin) | 0.10 ± 0.40 | -0.74 ± 0.73 | -0.39 ± 0.72 |
Values for change in FPG in mmol/L from baseline to week 26 of randomised period.
| mmol/L | IDeg | IDeg + Liraglutide | IDeg + IAsp OD |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) | -1.23 ± 2.03 | -0.14 ± 2.52 | -0.04 ± 2.84 |
Corresponds to the values of change in body weight in kilograms from baseline to week 26.
| kg | IDeg | IDeg + Liraglutide | IDeg + IAsp OD |
|---|---|---|---|
| Change From Baseline in Body Weight | 0.1 ± 2.7 | -1.0 ± 1.3 | 0.3 ± 0.9 |
Corresponds to number of treatment emergent hypoglycaemic events from onset on or after the first day of exposure to investigational product and no later than 7 days after last exposure to investigational product. Confirmed hypoglycaemia was defined as the pool of severe hypoglycaemic episodes and minor episodes with a plasma glucose (PG) value \< 3.1 mmol/L (56 mg/dL).
| events | IDeg | IDeg + Liraglutide | IDeg + IAsp OD |
|---|---|---|---|
| Confirmed(severe+minor) | 313 | 40 | 330 |
| Severe | 1 | 0 | 0 |
Collected over Treatment emergent adverse events were collected during 26 week treatment period + 7 days follow up.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IDeg | — | 11/236 (4.7%) | 64/236 (27.1%) |
| IDeg + Liraglutide | — | 4/87 (4.6%) | 40/87 (46%) |
| IDeg + IAsp OD | — | 5/86 (5.8%) | 18/86 (20.9%) |
| Event | IDeg | IDeg + Liraglutide | IDeg + IAsp OD |
|---|---|---|---|
| Vitreous detachmentEye disorders | 0/236 | 0/87 | 1/86 |
| PancreatitisGastrointestinal disorders | 0/236 | 0/87 | 1/86 |
| Humerus fractureInjury, poisoning and procedural complications | 0/236 | 0/87 | 1/86 |
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 0/236 | 0/87 | 1/86 |
| Cerebrovascular accidentNervous system disorders | 0/236 | 0/87 | 1/86 |
| Coronary artery diseaseCardiac disorders | 0/236 | 1/87 | 0/86 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/236 | 1/87 | 0/86 |
| Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/236 | 1/87 | 0/86 |
| Peripheral vascular disorderVascular disorders | 0/236 | 1/87 | 0/86 |
| Non-cardiac chest painGeneral disorders | 2/236 | 0/87 | 0/86 |
| Event | IDeg | IDeg + Liraglutide | IDeg + IAsp OD |
|---|---|---|---|
| NauseaGastrointestinal disorders | 3/236 | 18/87 | 1/86 |
| NasopharyngitisInfections and infestations | 43/236 | 9/87 | 11/86 |
| DiarrhoeaGastrointestinal disorders | 8/236 | 9/87 | 1/86 |
| Lipase increasedInvestigations | 0/236 | 6/87 | 0/86 |
| VomitingGastrointestinal disorders | 4/236 | 5/87 | 0/86 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 2/236 | 5/87 | 1/86 |
| BronchitisInfections and infestations | 13/236 | 1/87 | 2/86 |
| Upper respiratory tract infectionInfections and infestations | 12/236 | 4/87 | 3/86 |
The full analysis set (FAS) included all randomised patients except for 7 subjects (2 subjects with IDeg+ liraglutide; 5 subjects with IDeg+IAsp arm) fasting plasma glucose (FPG) values were missing at baseline. Non-randomised set (NAS) included all non-randomised subjects, the FPG values were missing for 10 subjects at baseline.
| Age, Continuous(years) | IDeg | IDeg + Liraglutide | IDeg + IAsp OD | Total |
|---|---|---|---|---|
| Mean | 61.9 ± 9.3 | NA ± NA | NA ± NA | 61.9 ± 9.3 |
| Age, Continuous(years) | IDeg | IDeg + Liraglutide | IDeg + IAsp OD | Total |
|---|---|---|---|---|
| Mean | NA ± NA | 61.1 ± 9.5 | 60.9 ± 8.8 | 61.0 ± 9.2 |
| Sex: Female, Male(Participants) | IDeg | IDeg + Liraglutide | IDeg + IAsp OD | Total |
|---|---|---|---|---|
| Female | 90 | NA | NA | NA |
| Male | 146 | NA | NA | NA |
| Sex: Female, Male(Participants) | IDeg | IDeg + Liraglutide | IDeg + IAsp OD | Total |
|---|---|---|---|---|
| Female | NA | 25 | 36 | NA |
| Male | NA | 63 | 53 | NA |
| Glycosylated haemoglobin (HbA1c)(percentage of glycosylated haemoglobin) | IDeg | IDeg + Liraglutide | IDeg + IAsp OD | Total |
|---|---|---|---|---|
| Mean | 6.4 ± 0.4 | NA ± NA | NA ± NA | 6.4 ± 0.4 |
| Glycosylated haemoglobin (HbA1c)(percentage of glycosylated haemoglobin) | IDeg | IDeg + Liraglutide | IDeg + IAsp OD | Total |
|---|---|---|---|---|
| Mean | NA ± NA | 7.7 ± 0.6 | 7.7 ± 0.8 | 7.7 ± 0.7 |
| Fasting plasma glucose (FPG)(mmol/L) | IDeg | IDeg + Liraglutide | IDeg + IAsp OD | Total |
|---|---|---|---|---|
| Mean | 6.7 ± 1.8 | NA ± NA | NA ± NA | 6.7 ± 1.8 |
| Fasting plasma glucose (FPG)(mmol/L) | IDeg | IDeg + Liraglutide | IDeg + IAsp OD | Total |
|---|---|---|---|---|
| Mean | NA ± NA | 6.4 ± 2.4 | 6.1 ± 1.7 | 6.3 ± 2.1 |
Showing the first 100 of 124 sites across 12 countries. Choose a country and city above to see the rest.
The record gives a start of Sep 2011, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 3 years 4 months after primary completion. A results delay was requested in Nov 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin degludec